Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG’s Daniel O’Day as its new chief executive, tapping an industry veteran to fill a management vacuum.
O’Day, now head of Roche’s pharmaceuticals business, joined the company in 1987 and held various roles in the United States before moving in 1998 to headquarters in Basel, Switzerland.
O’Day’s hiring comes about four months after Gilead said in July that Chief Executive John Milligan and Chairman John Martin would step down at the end of the year.
Jefferies analysts said in a note that O’Day’s three decades of oncology and global commercial expertise at Roche should help Gilead build out its own global presence, particularly in new areas it is entering including oncology and inflammation as well as through more acquisitions and in-licensing deals.
At Roche, O’Day was a champion of bi-specific antibodies that are under development as a potentially less expensive, less complicated alternative to CAR-T therapy where T cells must be taken out of the body, re-engineered and re-infused.
With Gilead’s Yescarta therapy, O’Day is now on the opposite side of the divide.
Separately, Roche said William Anderson, current CEO of its Genentech business, would replace O’Day next year.
Anderson joined Roche in 2006, leading the immunology business unit in Genentech, and then took charge of oncology sales and marketing. In 2013, he became head of global product strategy based in Basel before assuming his current role at Genentech in 2017.
Vontobel analyst Stefan Schneider called Anderson a “seasoned Roche manager” who played a key role in leading multiple sclerosis drug Ocrevus to success and driving double-digit growth in the U.S. market.
Gilead said on Monday that Martin would step down from the company’s board of directors, effective March 1, 2019.
Up to Friday’s close, the company’s shares have fallen nearly 14 percent since Milligan and Martin’s departures were announced by Gilead in July.
The Wall street Journal first reported O’Day’s hiring on Sunday.
Gilead said its board had appointed Gregg Alton as interim chief executive for the period of January 1, 2019 until O’Day’s start date of March 1, 2019.
Roche shares were down 0.6 percent by mid-morning, in line with the Stoxx European health care sector index.
By Liana Baker
Source: Reuters
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
